Report forecast the global migraine drugs market to
grow at a CAGR of 4.56% during the period 2016-2020.
A migraine is characterized by repeated attacks of
a severe headache, nausea, vomiting, and extreme sensitivity to light and
sound. Women are more prone to the disease compared to men owing to the
fluctuating levels of hormones in their bodies. Therapeutic agents such as
anti-inflammatory painkillers, antimigraine drugs, antisickness medicines, and
triptans are used for the treatment of the disease.
The report covers the present scenario and the
growth prospects of the global migraine drugs market for 2016-2020. To
calculate the market size, the report considers the revenue generated from the
sales of drugs that will be launched into the market along with the decline in
revenues from the patent expiries of the marketed drugs during the forecast
period.
The market is divided into the following
segments based on geography:
- Americas
- APAC
- EMEA
According to the report, a key market driver is the
unmet needs of migraine sufferers around the world. Prophylactic therapy with
improved efficacy and tolerability is one of the most significant unmet needs
in individuals suffering from migraine. The US Agency for Healthcare Research
and Quality estimated that only about 12% of the adults with migraines take
preventive medications. The occurrence of side effects is the major reason that
limits the use of migraine drugs. Moreover, there are still high levels of
unmet need existing in certain niche populations, especially in patients who do
not respond satisfactorily to triptans or patients for whom triptans are
contraindicated.
Further, the report states that a challenge that
could have a big impact on market growth is the lack of proper diagnosis of
migraines.
Global Migraine Drugs Market 2016-2020, has
been prepared based on an in-depth market analysis with inputs from industry
experts. The report covers the market landscape and its growth prospects over
the coming years. The report also includes a discussion of the key vendors
operating in this market.
key players in the Global Migraine Drugs Market:
Allergan, Endo International, GlaxoSmithKline, Impax, and Pfizer.
Other Prominent Vendors in the market are: Abbott,
Aegis Therapeutics, Aeriel BioPharma, Alder Biopharmaceuticals, Amgen,
Astellas, AstraZeneca, Bayer, CoLucid, Dr. Reddy’s Laboratories, Eisai, Eli
Lilly, Ethypharm, IntelGenx, Johnson & Johnson, Klaria, Kowa
Pharmaceuticals America, Luitpold Pharmaceuticals, Meda, Merck, OptiNose,
Pfizer, Pozen, Raptor, RedHill, SUDA, Teva, TG Therapeutics, NValeant, Winston
Pharmaceuticals, and Zogenix.
Market driver
- Growing awareness about migraine and its treatment options
- For a full, detailed list, view our report
Market challenge
- Lack of proper diagnosis
- For a full, detailed list, view our report
Market trend
- Antimigraine devices and headbands
- For a full, detailed list, view our report
Key questions answered in this report
- What will the market size be in 2020 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?
Spanning over 63 pages and 27 Exhibit “Global Migraine
Drugs Market 2016 - 2020” report covers Executive summary, Scope of the report,
Market research methodology, Introduction, Market landscape, Disease overview,
Pipeline analysis, Market segmentation by type of treatment, Market
segmentation by therapeutic class, Geographical segmentation, Market drivers,
Impact of drivers, Market challenges, Impact of drivers and challenges, Market
trends, Vendor landscape, Appendix.
For
more information Visit at: http://mrr.cm/JY2
Related Reports;
Global Ulcerative Colitis Market 2016-2020 - Visit
at - http://mrr.cm/JYu
Global Resipiratory Drugs Market 2016-2020 - Visit
at - http://mrr.cm/JYL
No comments:
Post a Comment
Note: only a member of this blog may post a comment.